glycine and glp 1 Glucagon-like peptide in health disease Effects of Replacing a Central
Description
...
Personalized care program designed to maximize the longevity benefits of GLP-1s.
The relative risk of symptomatic cholelithiasis was 1.6, 0.9, and 1.4 in liraglutide, dulaglutide, and semaglutide with number needed to harm of 3.14, 16.67, and 5.56, respectively
Patients who reduced the frequency of GLP-1 dosing (from weekly to every other week) were able to maintain their weight loss and metabolic syndrome gains, as reported in this case series
These early exits from therapy not only undermine clinical outcomes but also distort commercial forecasts and ROI projections
